- Home
- PMAX vs EDSA Comparison
PMAX vs EDSA Comparison
Compare PMAX & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMAX
- EDSA
- Stock Information
- Founded
- PMAX 2019
- EDSA 2015
- Country
- PMAX Hong Kong
- EDSA Canada
- Employees
- PMAX N/A
- EDSA N/A
- Industry
- PMAX
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- PMAX
- EDSA Health Care
- Exchange
- PMAX Nasdaq
- EDSA Nasdaq
- Market Cap
- PMAX 4.7M
- EDSA 6.2M
- IPO Year
- PMAX 2024
- EDSA N/A
- Fundamental
- Price
- PMAX $0.39
- EDSA $2.36
- Analyst Decision
- PMAX
- EDSA Strong Buy
- Analyst Count
- PMAX 0
- EDSA 1
- Target Price
- PMAX N/A
- EDSA $21.00
- AVG Volume (30 Days)
- PMAX 3.4M
- EDSA 9.0K
- Earning Date
- PMAX 05-06-2025
- EDSA 05-09-2025
- Dividend Yield
- PMAX N/A
- EDSA N/A
- EPS Growth
- PMAX N/A
- EDSA N/A
- EPS
- PMAX 0.04
- EDSA N/A
- Revenue
- PMAX $5,970,263.00
- EDSA N/A
- Revenue This Year
- PMAX N/A
- EDSA N/A
- Revenue Next Year
- PMAX N/A
- EDSA N/A
- P/E Ratio
- PMAX $9.14
- EDSA N/A
- Revenue Growth
- PMAX 30.05
- EDSA N/A
- 52 Week Low
- PMAX $0.28
- EDSA $1.55
- 52 Week High
- PMAX $4.70
- EDSA $5.59
- Technical
- Relative Strength Index (RSI)
- PMAX N/A
- EDSA 51.83
- Support Level
- PMAX N/A
- EDSA $2.29
- Resistance Level
- PMAX N/A
- EDSA $2.40
- Average True Range (ATR)
- PMAX 0.00
- EDSA 0.12
- MACD
- PMAX 0.00
- EDSA 0.00
- Stochastic Oscillator
- PMAX 0.00
- EDSA 87.88
About PMAX Powell Max Limited Class A Ordinary Shares
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. Key revenue is derived from Hong Kong.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.